Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

Classical vs reverse pharmacology in drug discovery.

Takenaka T.

BJU Int. 2001 Sep;88 Suppl 2:7-10; discussion 49-50. Review. No abstract available.

2.

Aminocyclohexylsulfonamides: discovery of metabolically stable alpha(1a/1d)-selective adrenergic receptor antagonists for the treatment of benign prostatic hyperplasia/lower urinary tract symptoms (BPH/LUTS).

Chiu G, Li S, Cai H, Connolly PJ, Peng S, Stauber K, Pulito V, Liu J, Middleton SA.

Bioorg Med Chem Lett. 2007 Nov 15;17(22):6123-8. Epub 2007 Sep 18.

PMID:
17904840
3.

New practical synthesis of Tamsulosin.

Gizur T, Fogassy E, Bálint J, Egri G, Törley J, Demeter A, Greiner I.

Chirality. 2008 Jun;20(6):790-5. doi: 10.1002/chir.20544.

PMID:
18306291
4.

Design and synthesis of an alpha1a-adrenergic receptor subtype-selective antagonist from BE2254.

Chiu G, Gluchowski C, Forray C.

Chem Biol Drug Des. 2006 Jun;67(6):437-9.

PMID:
16882319
5.

Evergreening: there's life in the old drug yet.

Wyllie MG.

BJU Int. 2005 Jun;95(9):1359-60. No abstract available.

6.

N-[3-(1H-imidazol-4-ylmethyl)phenyl]ethanesulfonamide (ABT-866, 1),(1) a novel alpha(1)-adrenoceptor ligand with an enhanced in vitro and in vivo profile relative to phenylpropanolamine and midodrine.

Altenbach RJ, Khilevich A, Meyer MD, Buckner SA, Milicic I, Daza AV, Brune ME, O'Neill AB, Gauvin DM, Cain JC, Nakane M, Holladay MW, Williams M, Brioni JD, Sullivan JP.

J Med Chem. 2002 Sep 26;45(20):4395-7.

PMID:
12238918
7.

[Latest frontiers in pharmacotherapy for benign prostatic hyperplasia].

Kawabe K.

Yakugaku Zasshi. 2006 Mar;126 Spec no.:199-206. Review. Japanese.

8.
9.

Effects of alpha 1-adrenergic receptor subtype selective antagonists on lower urinary tract function in rats with bladder outlet obstruction.

Gu B, Reiter JP, Schwinn DA, Smith MP, Korstanje C, Thor KB, Dolber PC.

J Urol. 2004 Aug;172(2):758-62.

PMID:
15247777
11.

Fragment-based drug discovery of carbonic anhydrase II inhibitors by dynamic combinatorial chemistry utilizing alkene cross metathesis.

Poulsen SA, Bornaghi LF.

Bioorg Med Chem. 2006 May 15;14(10):3275-84. Epub 2006 Jan 20.

PMID:
16431113
12.

Re: Effect of tamsulosin on systemic blood pressure and nonneurogenic dysfunctional voiding in children: B. A. Vanderbrink, J. Gitlin, S. Toro and L. S. Palmer J Urol 2009; 181: 817-822.

Yang SS, Chang SJ.

J Urol. 2009 Oct;182(4):1656-7; author reply 1657. doi: 10.1016/j.juro.2009.06.066. Epub 2009 Aug 15. No abstract available.

PMID:
19686960
13.

[Alpha1-adrenoceptor subtypes and alpha1-adrenoceptor antagonists].

Muramatsu I, Suzuki F, Tanaka T, Yamamoto H, Morishima S.

Yakugaku Zasshi. 2006 Mar;126 Spec no.:187-98. Review. Japanese.

14.

Design, synthesis, and biological evaluation of prazosin-related derivatives as multipotent compounds.

Antonello A, Hrelia P, Leonardi A, Marucci G, Rosini M, Tarozzi A, Tumiatti V, Melchiorre C.

J Med Chem. 2005 Jan 13;48(1):28-31.

PMID:
15633998
15.

Use of biomarkers from drug discovery through clinical practice: report of the Ninth European Federation of Pharmaceutical Sciences Conference on Optimizing Drug Development.

Rolan P, Atkinson AJ Jr, Lesko LJ; Scientific Organizing Committee; Conference Report Committee.

Clin Pharmacol Ther. 2003 Apr;73(4):284-91. No abstract available.

PMID:
12709718
16.
18.

Design, synthesis and evaluation of trifluoromethane sulfonamide derivatives as new potent and selective peroxisome proliferator-activated receptor alpha agonists.

Faucher N, Martres P, Laroze A, Pineau O, Potvain F, Grillot D.

Bioorg Med Chem Lett. 2008 Jan 15;18(2):710-5. Epub 2007 Nov 21.

PMID:
18060776
19.

Recent advances in selective alpha1-adrenoreceptor antagonists as antihypertensive agents.

Jain KS, Bariwal JB, Kathiravan MK, Phoujdar MS, Sahne RS, Chauhan BS, Shah AK, Yadav MR.

Bioorg Med Chem. 2008 May 1;16(9):4759-800. doi: 10.1016/j.bmc.2008.02.091. Epub 2008 Mar 4. Review.

PMID:
18378462
20.

Discovery and optimisation of a potent and selective tertiary sulfonamide oxytocin antagonist.

Barton NP, Bellenie BR, Doran AT, Emmons AJ, Heer JP, Salvagno CM.

Bioorg Med Chem Lett. 2009 Jan 15;19(2):528-32. doi: 10.1016/j.bmcl.2008.11.018. Epub 2008 Nov 12.

PMID:
19081251

Supplemental Content

Support Center